ArticleJournal of cachexia, sarcopenia and muscle2026
Dose-Response Association Between Handgrip Strength and All-Cause Mortality Across Different Levels of Systemic Inflammation.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLongitudinal associations between C-reactive protein (CRP) and handgrip strength from cohort studies remain inconsistent. We investigated the dose-response association between handgrip strength and all-cause mortality across different levels of systemic inflammation.
methodsWe analysed data from 20 941 participants (mean age 68 years ±9.4 SD; 43.1% men) from the Survey of Health, Ageing and Retirement in Europe (SHARE) Waves 6 to 9. CRP levels were categorized as > 3, > 10 and > 25 mg/L. Time-varying Cox proportional hazards regression with restricted cubic splines modeled associations between handgrip strength and all-cause mortality, adjusting for age, sex, BMI, smoking, education, marital status, geographic region and medications.
resultsDuring 4.8-5.3 years follow-up, mortalities were 14.7% (CRP > 3 mg/L), 22.5% (CRP > 10 mg/L) and 30.2% (CRP > 25 mg/L). A curvilinear dose-response association existed between handgrip strength and mortality across all CRP levels with a significant interaction found between CRP and handgrip strength (p = 0.0131). Using median handgrip strength as reference (30 kg for CRP > 3 mg/L; 28 kg for CRP > 10 and > 25 mg/L), participants at the 10th percentile showed hazard ratios of 1.84 (95% CI 1.59-2.14), 1.69 (95% CI 1.33-2.15) and 1.92 (95% CI 1.17-3.17), respectively. Participants at the 90th percentile demonstrated protective effects: HR 0.57 (95% CI 0.43-0.74), 0.50 (95% CI 0.30-0.82) and 0.38 (95% CI 0.17-0.87).
conclusionsHandgrip strength demonstrates a strong inverse dose-response association with mortality across varying inflammation levels. Protective effects persist even with elevated inflammatory markers, supporting handgrip strength as an accessible biomarker for mortality risk stratification in older adults regardless of inflammatory status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.